## 10/538758

## JC06 Rec'd PCT/PTO 10 JUN 2005

## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: O88484

Hiromu HABASHITA, et al.

Appln. No.: National Stage Entry of PCT/JP03/15718

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: June 10, 2005

Examiner: Unknown

For: NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE

Zaminineri Cinaro

THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith on CD-ROM, along with a copy of the corresponding Communication from a Foreign Patent Office, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

10/538758

JC06 Rec'd PCT/PTO 10 JUN 2005

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: National Stage Entry of PCT/JP03/15718

Attorney Docket No.: Q88484

The present Information Disclosure Statement is being filed: (1) No later than three months from

the application's filing date; (2) Before the mailing date of the first Office Action on the merits

(whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for

continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee

under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign

language documents, Applicant encloses herewith a copy of an English Language International Search

Report from the International Searching Authority in the International Application, including at least that

portion of the International Search Report indicating the degree of relevance found by the International

Searching Authority.

The submission of the listed documents is not intended as an admission that any such document

constitutes prior art against the claims of the present application. Applicant does not waive any right to

take any action that would be appropriate to antedate or otherwise remove any listed document as a

competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and

the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said

Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

Registration No. 32,197

SUGHRUE MION, PLLC Telephone: (202) 293-7060

Facsimile: (202) 293-7860 WASHINGTON OFFICE 23373

CUSTOMER NUMBER

Date: June 10, 2005

2

10/538**758** JC06 Rec'd PCT/PTO 10 JUN 2005.

				UCDO HOU GI GIII I	- MODITED 1100 D 00 11 W D (00		
				Complete if Known			
Substitute for Form 1449 A & B/PTO		· · · · · · · · · · · · · · · · · · ·	Application Number	National Stage Entry of PCT/JP03/15718			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Confirmation Number	Unknown		
				Filing Date	June 10, 2005		
				First Named Inventor	Hiromu HABASHITA		
(use as many sheets as necessary)				Art Unit	Unknown		
				Examiner Name	Unknown		
Sheet	1	of	1	Attorney Docket Number	Q88484		

	U.S. PATENT DOCUMENTS						
Examiner Initials*		Document Number		I T			
	Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
		US					
		US					
		US					
		US					
		US					
		US					
		US					
		US					
		US					

			FC	DREIGN PA	TENT DOCUM	ENTS		]
Examiner	Cite	Fo	reign Patent Docum	ent	Publication Date	Name of Patentee or	Translation <sup>6</sup>	1
Initials*	No.1	Country Code <sup>3</sup>	Number19684	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	I ranslation	ı
		-WO	00/56729	<del>-                                      </del>	09-28-2000	Anormed Inc.		1
		WO	00/30/23	4.2	02-20-2000	Anomica Inc.	-	1
***************************************	***************************************	44-0	OEI EESSS	1,62	-02-21-200E	TEHOTING THE:	***************************************	*
		-W-0	01/040227	<u> </u>	06-07-201	One Pharmaceutical Co.: Ltd.	····	+
		TD	2002 348288	<u> </u>	12.04.2002	One Phermacoutical Co. Ltd.		1
		WO	2002/45652	1.2	06.12.2002	Marale & Co		1
		GB	1113018	Δ.	05-15-1968	Farhenfahriken Bayer AG		1
		wo	2003/062236	Al	07-31-2003	Warner-Lambert Co		1
								T
								1
								1
								1
								1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation
		GUPTA, C.M. et al. "Drugs acting on the central nervous system. Synthesis of substituted quinazolinones and quinazolines and triazepino- and t	
		International Search Report dated February 17, 2004	

Examiner Signature //Noble Jatriell/ (02/20/2008) Date Considered

\*EXAMINER: Initial fireference considered, whether or not clustion is in conformance with MPEP 609. Draw line through clustion if not in conformance and not considered. Include copy of

'Applicant's unique citation designation number (options)). \*See Kind Codes of USPTO Patent Documents at www.uspna.gov, MPEP 901.04 or in the comment box of this document. \*2 Enter Office that issued the document, by the two-letter code (WIFO Standard ST. 3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Xind of document by the appropriate symbols as indicated on the document under WIFO Standard ST. 16 if possible. \*Applicant is to indicate here if English Inauguer Transitions is standerd.

this form with next communication to applicant.